The invention provides a novel anti-tumor fusion protein and application of the protein to the preparation of anti-tumor medicines. The anti-tumor fusion protein comprises at least one bioactivity molecule and a coiled coil structure field, wherein the bioactivity molecule is sourced from TNFSF10 and a modified TNFSF10, and the coiled coil structure field is sourced from a protein capable of naturally forming a polymer or is sourced from an artificial synthesis polypeptide sourced from a coil structure field capable of naturally forming a polymer protein. The coiled coil structure field in the fusion protein can naturally form a stable 3 alpha helix so as to help the fusion protein form a stable trimer structure. Compared with the natural TNFSF10, the fusion protein has better stability for easier storage, a more remarkable apoptosis induction action on a plurality of human body tumor cells in vitro, and the obviously improved anti-tumor activity.